loading
Emergent Biosolutions Inc stock is traded at $10.11, with a volume of 739.79K. It is up +0.80% in the last 24 hours and up +13.21% over the past month. Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$10.03
Open:
$10.05
24h Volume:
739.79K
Relative Volume:
0.40
Market Cap:
$539.13M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.8369
EPS:
-12.08
Net Cash Flow:
$-257.90M
1W Performance:
+13.85%
1M Performance:
+13.21%
6M Performance:
+112.39%
1Y Performance:
+388.41%
1-Day Range:
Value
$9.84
$10.33
1-Week Range:
Value
$8.83
$10.33
52-Week Range:
Value
$1.42
$15.10

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name
Name
Emergent Biosolutions Inc
Name
Phone
240-631-3200
Name
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Name
Employee
1,600
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
EBS's Discussions on Twitter

Compare EBS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
EBS
Emergent Biosolutions Inc
10.11 539.13M 1.02B -757.20M -257.90M -12.08
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
176.74 80.59B 9.15B 2.43B 2.31B 4.92
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.72 44.17B 14.26B 1.55B 0 0.3327
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.57 42.61B 30.27B 1.93B 3.45B 0.444
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.57 18.77B 16.77B -959.00M 1.37B -2.00
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
13.22 15.73B 15.05B -883.30M 1.89B 1.53

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-22-24 Initiated Rodman & Renshaw Buy
Mar-07-24 Upgrade The Benchmark Company Hold → Buy
Nov-20-23 Resumed JP Morgan Underweight
Aug-29-23 Downgrade The Benchmark Company Buy → Hold
Apr-10-23 Upgrade The Benchmark Company Hold → Buy
Mar-17-23 Downgrade JP Morgan Neutral → Underweight
Nov-10-22 Downgrade The Benchmark Company Buy → Hold
Apr-29-22 Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-20-22 Upgrade The Benchmark Company Hold → Buy
Nov-08-21 Downgrade The Benchmark Company Buy → Hold
May-05-21 Downgrade Argus Buy → Hold
Apr-07-21 Initiated The Benchmark Company Buy
Feb-24-21 Upgrade Chardan Capital Markets Neutral → Buy
Feb-19-21 Downgrade Chardan Capital Markets Buy → Neutral
Jan-08-21 Downgrade Wells Fargo Overweight → Equal Weight
Sep-14-20 Resumed JP Morgan Neutral
Jul-31-20 Reiterated Chardan Capital Markets Buy
Sep-12-19 Initiated Guggenheim Buy
Sep-04-19 Upgrade Wells Fargo Market Perform → Outperform
Nov-02-18 Upgrade Goldman Neutral → Buy
Aug-03-18 Reiterated Chardan Capital Markets Buy
Jun-13-18 Initiated Argus Buy
Apr-25-18 Downgrade Wells Fargo Outperform → Market Perform
Jan-24-18 Initiated Goldman Neutral
Jan-16-18 Reiterated Chardan Capital Markets Buy
Jun-28-16 Reiterated Singular Research Buy
Apr-15-16 Initiated Chardan Capital Markets Buy
Mar-28-16 Initiated Singular Research Buy
Feb-19-16 Initiated Wells Fargo Outperform
May-15-14 Initiated Summer Street Research Buy
May-31-11 Reiterated WBB Securities Strong Buy
Jan-10-11 Reiterated Wedbush Outperform
Nov-05-10 Reiterated Wedbush Outperform
Aug-18-10 Upgrade WBB Securities Buy → Strong Buy
Aug-06-10 Reiterated Caris & Company Buy
View All

Emergent Biosolutions Inc Stock (EBS) Latest News

pulisher
Nov 23, 2024

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN

Nov 23, 2024
pulisher
Nov 22, 2024

Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement - Benzinga

Nov 22, 2024
pulisher
Nov 20, 2024

Emergent BioSolutions Inc. (NYSE:EBS) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com - MarketBeat

Nov 20, 2024
pulisher
Nov 14, 2024

Insider Sale: Director Donald Degolyer Sells 25,000 Shares of Em - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock By Investing.com - Investing.com UK

Nov 14, 2024
pulisher
Nov 14, 2024

Oak Hill Advisors LP's Strategic Acquisition of Emergent BioSolu - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Insider Sale: Director Marvin White Sells 14,287 Shares of Emergent BioSolutions Inc (EBS) - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Smallpox Treatment Market Is Anticipated To Grow In A Promising - openPR

Nov 13, 2024
pulisher
Nov 12, 2024

Emergent BioSolutions Inc (EBS) Shares Down 8.02% on Nov 12 - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

IDWeek 2024: strategic approaches and challenges in mpox vaccination - Pharmaceutical Technology

Nov 12, 2024
pulisher
Nov 09, 2024

Emergent BioSolutions Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Emergent BioSolutions (NYSE:EBS) Shares Up 7.9% After Analyst Upgrade - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic (NYSE:EBS) - Seeking Alpha

Nov 08, 2024
pulisher
Nov 08, 2024

Emergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment Strong - MSN

Nov 08, 2024
pulisher
Nov 07, 2024

Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Emergent BioSolutions Inc (EBS) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Emergent BioSolutions entering ‘turnaround’ phase, new CEO says - The Business Journals

Nov 07, 2024
pulisher
Nov 07, 2024

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Crude Oil Rises 1%; US Jobless Claims Increase To 221,000 - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Emergent BioSolutions (NYSE:EBS) Shares Gap Up on Analyst Upgrade - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Emergent Biosolutions Shares Surge 28% After Swinging to 3Q Profit - MarketWatch

Nov 07, 2024
pulisher
Nov 07, 2024

Emergent BioSolutions stock target increased, keeps buy on strong Q3 By Investing.com - Investing.com UK

Nov 07, 2024
pulisher
Nov 07, 2024

The Post-Trump Victory TradeEmergent BioSolutions (NYSE:EBS), Bit Digital (NASDAQ:BTBT) - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Emergent Biosolutions: Q3 Earnings Snapshot - Houston Chronicle

Nov 07, 2024
pulisher
Nov 07, 2024

Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript - AOL

Nov 07, 2024
pulisher
Nov 06, 2024

Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Emergent Biosolutions stock jumps 14% post-market on guidance raise (NYSE:EBS) - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

The Escalator: Emergent BioSolutions, CureVac, Kyowa Kirin and more - MM+M Online

Nov 06, 2024
pulisher
Nov 06, 2024

Emergent BioSolutions Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Emergent BioSolutions Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024
pulisher
Nov 05, 2024

Emergent Bio slips after financing deal - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Emergent BioSolutions appoints new chief medical officer By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 04, 2024

Biotech Co. Emergent Gives Interim GC Permanent Role - Law360

Nov 04, 2024
pulisher
Nov 04, 2024

Emergent BioSolutions appoints new chief medical officer - Investing.com

Nov 04, 2024
pulisher
Oct 30, 2024

Emergent BioSolutions (EBS) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Emergent Bio's smallpox vaccine gets US approval for mpox - AOL

Oct 29, 2024
pulisher
Oct 29, 2024

Assenagon Asset Management S.A. Increases Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way? - Simply Wall St

Oct 28, 2024
pulisher
Oct 28, 2024

Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store - Yahoo Finance

Oct 28, 2024
pulisher
Oct 25, 2024

5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades - Yahoo Finance

Oct 25, 2024
pulisher
Oct 25, 2024

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - GlobeNewswire Inc.

Oct 25, 2024
pulisher
Oct 23, 2024

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference - The Bakersfield Californian

Oct 23, 2024
pulisher
Oct 21, 2024

Emergent BioSolutions (NYSE:EBS) Shares Up 3.2%Here's What Happened - MarketBeat

Oct 21, 2024
pulisher
Oct 15, 2024

Biopharma Layoffs Roundup - Contract Pharma

Oct 15, 2024

Emergent Biosolutions Inc Stock (EBS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$90.27
price up icon 0.83%
$13.13
price up icon 0.00%
$86.59
price up icon 0.19%
$61.00
price up icon 0.41%
$126.59
price down icon 1.03%
$13.22
price up icon 1.07%
Cap:     |  Volume (24h):